Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Soticlestat is an inhibitor of cholesterol 24-hydroxylase/CYP46A1 (IC50 = 0.0074 µM).1 It is selective for cholesterol 24-hydroxylase/CYP46A1 over the cytochrome P450 (CYP) isoforms CYP2C8, -2C9, -2D6, -3A4, -1A2, and 2C19 (IC50s = 62, 19, >100, 66, >100, and 14 µM, respectively). Soticlestat (0.02% in the diet) reduces seizure frequency and severity and improves survival in a model of Dravet syndrome induced by hyperthermia in mice with heterozygous deletion of Scn1a (Scn1a+/-), the gene encoding voltage-gated sodium channel 1.1 (Nav1.1).2
WARNING This product is not for human or veterinary use.
1. Discovery of soticlestat, a potent and selective inhibitor for cholesterol 24-
2. Soticlestat, a novel cholesterol 24-